Short answer
SUPERNUS PHARMACEUTICALS, INC. (SUPN) filed an 8-K current report with the SEC on May 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Filing contains only Form 8-K signatures dated May 5, 2026.
SUPERNUS PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Filing contains only Form 8-K signatures dated May 5, 2026
- No earnings results or operating metrics provided in the submitted Item 2.02 text
- Investors must review the referenced earnings exhibit for financial performance details
Item EX-99.1 · Exhibit EX-99.1
- Q1 2026 revenue $207.7M, up 39%, driven by growth products and $20.0M Shionogi commercial milestone licensing revenue
- Growth-product revenue rose 56% to $149.1M, led by Qelbree $77.9M, ZURZUVAE collaboration revenue $27.6M, and GOCOVRI $35.2M
- ONAPGO generated $8.4M sales after February patient-initiation resumption; second-supplier FDA submission expected Q3 2026
- Net loss narrowed to $2.3M, or $0.04 per share, while adjusted operating earnings increased to $28.7M
- 2026 guidance reaffirmed: revenue $840M–$870M, GAAP operating earnings $0M–$30M, adjusted operating earnings $140M–$170M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other SUPERNUS PHARMACEUTICALS, INC. 8-K filings
Get the next SUPN 8-K as it lands
Follow SUPN for push alerts, or ask the research agent what this filing means.